Clinical trials / NCT05987332
NCT05987332Phase 2, phase 3Active not recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Study sponsor: IDEAYA Biosciences

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2027-01-15Estimated
Enrollment · participants420Estimated
Source updated2026-02-17Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Progression-Free Survival (PFS) by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment Measure: Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment

+ After

Measure: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: Measure: Phase 2 Progression-Free Survival (PFS) Measure: Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source